Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, February 19, 2025. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day.

Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). The webcast and accompanying slides will be available in the Investor section of Karyopharm's website under 'Events & Presentations', with an archived version accessible approximately two hours after the event.

-- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET --

NEWTON, Mass., Feb. 12, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, February 19, 2025, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-19-2025-302372912.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm (KPTI) release Q4 and full year 2024 earnings?

Karyopharm will release its Q4 and full year 2024 financial results on Wednesday, February 19, 2025.

What time is KPTI's Q4 2024 earnings call?

Karyopharm's Q4 2024 earnings conference call is scheduled for 8:00 a.m. ET on Wednesday, February 19, 2025.

How can investors access KPTI's Q4 2024 earnings call?

Investors can access the call by dialing (800) 836-8184 (local) or (646) 357-8785 (international), or via webcast on the company's investor relations website.

Where can I find KPTI's Q4 2024 earnings presentation slides?

The presentation slides will be available under 'Events & Presentations' in the Investor section of Karyopharm's website at http://investors.karyopharm.com/events-presentations.